GR3030823T3 - 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht 4? or h 3? receptor ligands - Google Patents

5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht 4? or h 3? receptor ligands

Info

Publication number
GR3030823T3
GR3030823T3 GR990401913T GR990401913T GR3030823T3 GR 3030823 T3 GR3030823 T3 GR 3030823T3 GR 990401913 T GR990401913 T GR 990401913T GR 990401913 T GR990401913 T GR 990401913T GR 3030823 T3 GR3030823 T3 GR 3030823T3
Authority
GR
Greece
Prior art keywords
oxadiazol
piperidin
phenyl
derivatives
receptor ligands
Prior art date
Application number
GR990401913T
Other languages
Greek (el)
English (en)
Inventor
Samir Jegham
Alistair Lochead
Frederic Galli
Alain Nedelec
Axelle Solignac
Cruz Laurence De
Original Assignee
Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9513252A external-priority patent/FR2741069B1/fr
Priority claimed from FR9513253A external-priority patent/FR2741070B1/fr
Priority claimed from FR9602663A external-priority patent/FR2745574B1/fr
Application filed by Synthelabo filed Critical Synthelabo
Publication of GR3030823T3 publication Critical patent/GR3030823T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
GR990401913T 1995-11-09 1999-07-20 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht 4? or h 3? receptor ligands GR3030823T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9513252A FR2741069B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9513253A FR2741070B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9602663A FR2745574B1 (fr) 1996-03-04 1996-03-04 Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique
PCT/FR1996/001730 WO1997017345A1 (fr) 1995-11-09 1996-11-05 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one, utiles comme ligands des recepteurs 5-ht4 ou h¿3?

Publications (1)

Publication Number Publication Date
GR3030823T3 true GR3030823T3 (en) 1999-11-30

Family

ID=27253120

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990401913T GR3030823T3 (en) 1995-11-09 1999-07-20 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht 4? or h 3? receptor ligands

Country Status (29)

Country Link
US (1) US5929089A (OSRAM)
EP (1) EP0863897B1 (OSRAM)
JP (1) JP4263240B2 (OSRAM)
CN (1) CN1077891C (OSRAM)
AR (1) AR004708A1 (OSRAM)
AT (1) ATE181328T1 (OSRAM)
AU (1) AU707325B2 (OSRAM)
BG (1) BG63463B1 (OSRAM)
BR (1) BR9611311A (OSRAM)
CA (1) CA2236357C (OSRAM)
CO (1) CO4770968A1 (OSRAM)
CZ (1) CZ287268B6 (OSRAM)
DE (1) DE69602970T2 (OSRAM)
EE (1) EE03487B1 (OSRAM)
ES (1) ES2135934T3 (OSRAM)
GR (1) GR3030823T3 (OSRAM)
HU (1) HUP0001168A3 (OSRAM)
IL (1) IL124364A (OSRAM)
MX (1) MX9803696A (OSRAM)
NO (1) NO309606B1 (OSRAM)
NZ (1) NZ321626A (OSRAM)
PL (1) PL186204B1 (OSRAM)
RU (1) RU2167160C2 (OSRAM)
SI (1) SI0863897T1 (OSRAM)
SK (1) SK282335B6 (OSRAM)
TR (1) TR199800827T2 (OSRAM)
TW (1) TW371303B (OSRAM)
UA (1) UA50748C2 (OSRAM)
WO (1) WO1997017345A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
FR2762316B1 (fr) * 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
JP2002504896A (ja) * 1997-05-06 2002-02-12 サノフィ−サンテラボ ５−フェニル−１，３，４−オキサジアゾール−２（３ｈ）−オン誘導体およびそれらの５−ｈｔ４リガンドとしての使用
FR2763068B1 (fr) 1997-05-06 1999-06-04 Synthelabo Derives de 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
GB9715816D0 (en) * 1997-07-25 1997-10-01 Black James Foundation Histamine H receptor ligands
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
DK1112106T3 (da) 1998-09-18 2005-12-12 Alcon Mfg Ltd Serotonerge 5HT2-agonister til behandling af glaukom
EP1173168A2 (en) * 1999-04-28 2002-01-23 Respiratorius AB Compound for use as a medicament for treatment of disorders involving bronchocontraction
JP2003501462A (ja) * 1999-06-15 2003-01-14 レスピラトリウス アクチボラゲット 受容体アゴニストおよびアンタゴニスト
DK1313721T3 (da) 2000-08-08 2006-06-26 Ortho Mcneil Pharm Inc Ikke-imidazol-aryloxyalkylaminer som H3-receptorligander
HUP0302893A3 (en) 2000-08-08 2006-04-28 Ortho Mcneil Pharm Inc Non-imidazole aryloxypiperidines and pharmaceutical compositions containing them and their use
AU2001281119A1 (en) * 2000-08-08 2002-02-18 Ortho-Mcneil Pharmaceutical, Inc. Bicyclic compounds as h3 receptor ligands
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
ATE449090T1 (de) 2001-07-02 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
ATE450508T1 (de) * 2001-09-14 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
ATE479655T1 (de) 2001-09-14 2010-09-15 High Point Pharmaceuticals Llc Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
CA2469663A1 (en) 2001-12-14 2003-06-26 Alcon, Inc. Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
CA2569654C (en) 2004-06-15 2010-12-21 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
CA2614116A1 (en) 2005-07-04 2007-01-11 Novo Nordisk A/S Novel medicaments
CN101321525B (zh) * 2005-12-01 2013-01-30 霍夫曼-拉罗奇有限公司 作为l-cpt1抑制剂的杂芳基取代的哌啶衍生物
SI2079732T1 (sl) 2006-05-29 2012-03-30 High Point Pharmaceuticals Llc benzodioksol il ciklopropilpiperazin il piridazin njegove soli in solvati in njegova uporaba kot antagonist histaminskega receptorja H
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
PL2758394T3 (pl) * 2011-09-19 2015-08-31 Suven Life Sciences Ltd Związki heteroarylowe jako ligandy receptora 5-HT4

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055476A (en) * 1990-08-13 1991-10-08 Hoechst-Roussel Pharmaceuticals Incorporated 3-(1,2-benzisoxazol-3-yl)-4-pyridinamines and derivatives
WO1993003725A1 (en) * 1991-08-20 1993-03-04 Smithkline Beecham Plc 5-ht4 receptor antagonists
JP3294611B2 (ja) * 1991-09-12 2002-06-24 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５−ｈｔ４レセプター・アンタゴニスト
JPH07503480A (ja) * 1992-02-06 1995-04-13 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５−ｈｔ４拮抗薬としてのベンゾピラン，ベンゾチオピランおよびベンゾフラン誘導体
GB9219163D0 (en) * 1992-09-10 1992-10-28 Smithkline Beecham Plc Pharmaceuticals
JPH06157518A (ja) * 1992-11-27 1994-06-03 Yamanouchi Pharmaceut Co Ltd 新規なオキサジアゾール誘導体又はその塩

Also Published As

Publication number Publication date
JP2000500125A (ja) 2000-01-11
EP0863897A1 (fr) 1998-09-16
HK1016165A1 (en) 1999-10-29
BG63463B1 (bg) 2002-02-28
NO982092D0 (no) 1998-05-07
ES2135934T3 (es) 1999-11-01
NO309606B1 (no) 2001-02-26
IL124364A (en) 2001-08-08
DE69602970T2 (de) 2000-01-20
AR004708A1 (es) 1999-03-10
CA2236357C (en) 2006-10-17
PL186204B1 (pl) 2003-11-28
SK59998A3 (en) 1998-11-04
CO4770968A1 (es) 1999-04-30
AU707325B2 (en) 1999-07-08
EP0863897B1 (fr) 1999-06-16
PL326671A1 (en) 1998-10-12
MX9803696A (es) 1998-09-30
US5929089A (en) 1999-07-27
NZ321626A (en) 1998-10-28
SI0863897T1 (en) 1999-10-31
CN1202169A (zh) 1998-12-16
UA50748C2 (uk) 2002-11-15
NO982092L (no) 1998-06-29
CN1077891C (zh) 2002-01-16
ATE181328T1 (de) 1999-07-15
SK282335B6 (sk) 2002-01-07
HUP0001168A3 (en) 2001-07-30
IL124364A0 (en) 1998-12-06
CA2236357A1 (en) 1997-05-15
DE69602970D1 (de) 1999-07-22
AU7500196A (en) 1997-05-29
BG102412A (en) 1999-08-31
RU2167160C2 (ru) 2001-05-20
BR9611311A (pt) 1999-06-29
CZ142198A3 (cs) 1998-08-12
EE03487B1 (et) 2001-08-15
TR199800827T2 (xx) 1999-02-22
EE9800155A (et) 1998-12-15
TW371303B (en) 1999-10-01
WO1997017345A1 (fr) 1997-05-15
HUP0001168A2 (hu) 2001-04-28
JP4263240B2 (ja) 2009-05-13
CZ287268B6 (en) 2000-10-11

Similar Documents

Publication Publication Date Title
GR3030823T3 (en) 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht 4? or h 3? receptor ligands
GR3035075T3 (en) Indole derivatives as 5-ht receptor antagonist
SI0975631T1 (en) 5-aryl-3-(8-azabicyclo(3.2.1)oct-3-yl)-1,3,4-oxadiazol-2(3h)-one derivatives as 5-ht4 receptor ligands
IL108784A0 (en) Use of 2h-1,2,4-benzothiadiazin-3(4h)-one 1,1-dioxide derivatives as noncompetitive antagonists of the mmda receptor
GR3034397T3 (en) Condensed thiazole derivatives, having 5-ht receptor affinity
HUP9701115A3 (en) N-acetonylbenzamide derivatives, process for the preparation thereof, fungicide compositions containing these compounds and use thereof
HUP9600333A2 (en) Azole derivatives as adhesive receptor antagonists, pharmaceutical compositions containing the same and process for their preparation
ZA9600758D (en) Idole derivatives as 5-ht receptor antagonist.
HUP9801716A3 (en) 5h,10h-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one derivatives, ph
ZA969418B (en) 5-Phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol 2(3H)-one derivatives their preparation and their application in therapeutics
DK0863897T3 (da) Derivater af 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-on, som kan anvendes som ligander for 5-HT4- eller H3-recept
AU7658798A (en) 5-phenyl-1,3,4-oxadiazol-2(3h)-one derivatives and their use as 5-ht4 ligands
ZA983776B (en) 3-(pyrrolidin-3-yl)-1, 3, 4-oxadiazol-2(3h)-one derivatives their preparation and their therapeutic application
SI0836606T1 (en) Condensed thiazole derivatives, having 5-ht receptor affinity
HU9503566D0 (en) Hygenic part for wc seat
FR2745574B1 (fr) Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique
SG66225A1 (en) Novel 1-phenylalkanone 5-ht receptor ligands
ZA926208B (en) 5-Ht 4 receptor antagonists.
TW349440U (en) Improvement for adjustable type multiple axis drill seat
SI1019385T1 (en) Aminoaryl oxazolidinone n-oxides